DDB2 and head and neck squamous cell carcinoma: Collectively, our results demonstrate that systemic administration of pevonedistat significantly decreases DDB2 expression, which promotes enhanced sensitivity to cisplatin resulting in long-term survival of HNSCC tumor-bearing animals.